TGFB1 and neoplasm: Multiple studies have reported that the expression of miR-5195-3p was downregulated in cervical, triple-negative breast, and colon cancer, which reduces the chemotherapy sensitivity of tumor cells to paclitaxel and inhibits the TGF-β signaling pathway and cell cycle progression, leading to malignant tumor progression [26].